Terms: = Pancreatic cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Clinical Outcome
3 results:
1. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
2. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
[TBL] [Abstract] [Full Text] [Related]
3. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by foxp3+ regulatory T cells.
Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
[TBL] [Abstract] [Full Text] [Related]
